2015
Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease
Sun H, Palcza J, Rosenberg R, Kryger M, Siringhaus T, Rowe J, Lines C, Wagner JA, Troyer MD. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease. Respiratory Medicine 2015, 109: 416-426. PMID: 25661282, DOI: 10.1016/j.rmed.2014.12.010.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAzepinesCross-Over StudiesDouble-Blind MethodFemaleHumansMaleMiddle AgedOrexin Receptor AntagonistsPulmonary Disease, Chronic ObstructiveRespirationSeverity of Illness IndexSleepSleep Aids, PharmaceuticalSpirometryTreatment OutcomeTriazolesUnited StatesConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseSleep breathing disordersOrexin receptor antagonistPulmonary diseaseBreathing disordersReceptor antagonistModerate chronic obstructive pulmonary diseaseDay 4Effects of suvorexantModerate airflow limitationRespiratory depressant effectsApnea-hypopnea indexMaximum daily doseClinical research unitTotal sleep timeTreatment of insomniaMean AHICOPD patientsAirflow limitationHypopnea indexDaily doseMean SpO2Spirometry criteriaHypnotic medications
1997
Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy
Broughton R, Fleming J, George C, Hill J, Kryger M, Moldofsky H, Montplaisir J, Morehouse R, Moscovitch A, Murphy W. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997, 49: 444-451. PMID: 9270575, DOI: 10.1212/wnl.49.2.444.Peer-Reviewed Original ResearchConceptsPlacebo-controlled crossover trialOnly significant adverse effectPlacebo-controlled trialExcessive daytime somnolenceMean sleep latencyPeriodic leg movementsEpworth Sleepiness ScaleDaytime sleep episodesInternational diagnostic criteriaSignificant adverse effectsHypertensive patientsMore nauseaBlood pressureDaily doseDaytime somnolenceExcessive daytimeSleep apneaCrossover trialSleep latencyModafinil 200Nocturnal sleepPatient's abilitySleepiness ScaleSleep initiationHeart rate